TrialHuman vaccines & immunotherapeutics2022

Safety and immunogenicity of 3 formulations of a Sabin inactivated poliovirus vaccine produced on the PER.C6® cell line: A phase 2, double-blind, randomized, controlled study in infants vaccinated at 6, 10 and 14 weeks of age.

Anna Lisa Ong-Lim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.